News | May 31, 2025
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Akums invested Rs. 272 crore in capital expenditure during FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Allopurinol is used to prevent or lower high uric acid levels in the blood
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated
